Dynamics of NT-proBNP and ST2 levels as markers of heart failure in patients with endogenous Cushing syndrome (hypercortisolism)
Open Access
- 16 January 2023
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (12) , 1387-1393
Abstract
Aim. To evaluate frequency of heart failure syndrome in patients with endogenous hypercortisolism and to establish relationship between effective treatment for hypercortisolism and regression of heart failure with particular emphasis on the observation of NT-proBNP and ST2 levels. Materials and methods. 56 patients with endogenous hypercortisolism (45 female, mean age 47 years [36; 55] hospitalized with endogenous hypercortisolism to National Medical Research Center for Endocrinology were enrolled in the study. All patients underwent comprehensive clinical investigation including expert echocardiography with speckle tracking and evaluation of NT-proBNP and ST2 cardiac biomarkers at baseline and 6 months after surgical treatment. Results. According to clinical data and elevated biomarkers of cardiac stress 28 out of 56 patients (50%) at baseline met the criteria for heart failure. 20 patients were included in the final analysis. Follow-up investigation with focus on changes in NT-proBNP and ST2 levels demonstrated that surgical correction of endogenous hypercortisolism resulted in resolution of heart failure syndrome in 11 patients (55%). Conclusion. These preliminary data suggest that signs and symptoms of heart failure are observed in patients with endogenous hypercortisolism in about half the cases. Surgical correction results in resolution of heart failure in approximately two thirds of the cases. Prospective evaluation NT-proBNP and ST2 levels may provide important diagnostic and prognostic information in patients with endogenous hypercortisolism.Keywords
This publication has 14 references indexed in Scilit:
- Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort studyThe Lancet Diabetes & Endocrinology, 2016
- Cushing's syndromeThe Lancet, 2015
- Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2015
- Cushing’s disease: the clinical features, diagnostics, differential diagnostics, and methods of treatmentProblems of Endocrinology, 2015
- MANAGEMENT OF ENDOCRINE DISEASE: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysisEuropean Journal of Endocrinology, 2015
- The hypertension of Cushing's syndromeJournal Of Hypertension, 2015
- Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging StudyThe Journal of Clinical Endocrinology & Metabolism, 2014
- Soluble ST2 and Galectin-3 in Heart FailureClinics In Laboratory Medicine, 2014
- Prognostic Utility of Novel Biomarkers of Cardiovascular StressCirculation, 2012
- THROMBOEMBOLIC COMPLICATIONS IN CUSHING'S SYNDROMEClinical Endocrinology, 1983